Agents used to control end-of-life suffering are associated with troublesome side effects. The use of @entity6948 for sedation during withdrawal of support in pediatrics is not yet described. An adolescent female with progressive and irreversible @entity358 was admitted. Despite weeks of therapy, she did not tolerate weaning of supplemental @entity26 or continuous bilevel positive airway pressure. Given her condition and the perception that she was suffering, the family requested withdrawal of support. Despite opioids and @entity1245 , she appeared to be uncomfortable after support was withdrawn. @entity3652 was initiated. Relief from @entity3652 was brief, and its use was associated with a "wide-eyed" look that was distressing to the family. @entity3652 was discontinued and a @entity6948 infusion was initiated. The @entity1 's level of comfort improved greatly. The @entity1 died peacefully 24 hours after initiating @entity6948 from her underlying disease rather than the effects of the sedative.

XXXX for Sedation during Withdrawal of Support.

@entity1 :: ('9606', 'Species') :: ['child', 'patient'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity3652 :: ('MESH:D007649', 'Chemical') :: ['ketamine', 'Ketamine'] @entity1245 :: ('MESH:D001569', 'Chemical') :: ['benzodiazepines'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary deterioration'] @entity6948 :: ('MESH:D020927', 'Chemical') :: ['dexmedetomidine']
@entity6948 :: (MESH:D020927,Chemical) :: ['Dexmedetomidine']
